研究单位：[1]Eli Lilly and Company[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Anhui Provincial Hospital Hefei,Anhui,China,230001[4]Sun Yat-sen Memorial Hospital,Sun Yat-sen University Guangzhou,Guangdong,China,510120[5]Shenzhen People's Hospital Shenzhen,Guangdong,China,518020[6]1st Hospital affiliated to Medical College of Shantou Univer Shantou,Guangzhou,China,515041[7]Wuhan Union Hospital Wuhan,Hubei,China,430022[8]Wu Han Tongji Hospital Wuhan,Hubei,China,430030[9]ZhuZhou Central Hospital ZhuZhou,Hunan,China,412007[10]The First Affiliated Hospital of Baotou Medical College Baotou,Inner Mongolia,China,014000
研究目的：
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
